The Coverage of Registration of Drugs Resistant Tuberculosis Patients in Health Region 4, Fiscal Year 2020

Abstract

A cross-sectional descriptive study aimed to explore the coverage of drug-resistant tuberculosis patient’s registration in health region 4 in the fiscal year 2019. The study population was tuberculosis patients who registered for treatment in the National Tuberculosis Information Program (NTIP) of the hospitals in the health region 4. A total of 127 cases were identified in NTIP, compared to laboratory results that used Xpert MTB/RIF, Line Probe Assay (LPA), culture and drug susceptibility testing (DST) for examination. The data of first-line and second-line anti-tuberculosis drug resistance was collected from October 2019 to September 2020 by using case record form. The data were analyzed by using descriptive statistics such as percentages. The study found that drug-resistant tuberculosis patients registered for about 127 cases in NTIP. And also, 11 cases not registered, died before registration. The cause of death was respiratory failure. The study suggested that prevention and control of drug-resistant tuberculosis should be focused on complete registration for treatment. It affected early treatment and helped to obstacle the transmission of drug-resistant tuberculosis to others. Also, surveillance systems in health care providers and contact cases should be conducted continuously.